OBJECTIVES: To evaluate the ability of prostate mechanical imaging (PMI) technology to provide an objective and reproducible image and to assess the prostate nodularity. METHODS: We evaluated the PMI device developed by Artann Laboratories in a pilot clinical study. For the 168 patients (ages 44 to 94) who presented to an urologist for prostate evaluation, PMI-produced images and assessment of prostate size, shape, consistency/hardness, mobility, and nodularity were compared with digital rectal examination (DRE) findings. The PMI and DRE results were further tested for correlation against a transrectal ultrasound of the prostate (TRUS) guided biopsy for a subgroup of 21 patients with an elevated prostate-specific antigen level. RESULTS: In 84% of the cases, the PMI device was able to reconstruct three-dimensional (3D) and 2D cross-sectional images of the prostate. The PMI System and DRE pretests were able to determine malignant nodules in 10 and 6 patients, respectively, of the 13 patients with biopsy-confirmed malignant inclusions. The PMI System findings were consistent with all 8 biopsy negative cases, whereas the DRE had 1 abnormal reading for this group. The correlation between PMI and DRE detection of palpable nodularity was 81%, as indicated by the area under the receiver operating characteristic curve. Estimates of the prostate size provided by PMI and DRE were statistically significantly correlated. CONCLUSIONS: The PMI has the potential to enable a physician to obtain, examine, and store a 3D image of the prostate based on mechanical and geometrical characteristics of the gland and its internal structures.
OBJECTIVES: To evaluate the ability of prostate mechanical imaging (PMI) technology to provide an objective and reproducible image and to assess the prostate nodularity. METHODS: We evaluated the PMI device developed by Artann Laboratories in a pilot clinical study. For the 168 patients (ages 44 to 94) who presented to an urologist for prostate evaluation, PMI-produced images and assessment of prostate size, shape, consistency/hardness, mobility, and nodularity were compared with digital rectal examination (DRE) findings. The PMI and DRE results were further tested for correlation against a transrectal ultrasound of the prostate (TRUS) guided biopsy for a subgroup of 21 patients with an elevated prostate-specific antigen level. RESULTS: In 84% of the cases, the PMI device was able to reconstruct three-dimensional (3D) and 2D cross-sectional images of the prostate. The PMI System and DRE pretests were able to determine malignant nodules in 10 and 6 patients, respectively, of the 13 patients with biopsy-confirmed malignant inclusions. The PMI System findings were consistent with all 8 biopsy negative cases, whereas the DRE had 1 abnormal reading for this group. The correlation between PMI and DRE detection of palpable nodularity was 81%, as indicated by the area under the receiver operating characteristic curve. Estimates of the prostate size provided by PMI and DRE were statistically significantly correlated. CONCLUSIONS: The PMI has the potential to enable a physician to obtain, examine, and store a 3D image of the prostate based on mechanical and geometrical characteristics of the gland and its internal structures.
Authors: Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer Journal: J Natl Cancer Inst Date: 2002-07-03 Impact factor: 13.506
Authors: Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning Journal: J Natl Cancer Inst Date: 2003-06-18 Impact factor: 13.506
Authors: Magnus Törnblom; Henry Eriksson; Stefan Franzén; Ove Gustafsson; Hans Lilja; Ulf Norming; Jonas Hugosson Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Armen Sarvazyan; Timothy J Hall; Matthew W Urban; Mostafa Fatemi; Salavat R Aglyamov; Brian S Garra Journal: Curr Med Imaging Rev Date: 2011-11